evere hepatitis is the most severe liver disease, with poor prognosis and high mortality. We explored the practical use of the model for end-stage liver disease (MELD) on clinical and the molecular adsorbents recirculating system (MARS) on chronic severe hepatitis to predict the short-term prognosis of patients with chronic severe hepatitis using the MELD score and the curative effect of MARS treatment. 
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METHODS

Patients
We collected hospital records of 60 patients with hepatitis B virus (HBV) 
Treatment
Standard medical therapy was similar in the two groups. MARS treatment was carried on in the MARS group in addition to the standard medical therapy. Intrajugular double-lumen catheter was maintained before the MARS treatment, and the circulation blood flow rate and the circulation albumin flow rate both were 150 ml/min.
Laboratory test and MELD score
We collected the initial laboratory test results of 60 patients at referral and observed the outcome of the patients within 3 months after admission. The MELD equation was as follows: MELD score = 3.8 × log bilirubin (mg/dl) + 11.2 × log international normalized ratio (INR) + 9.6 × log creatinine (mg/dl) + 6.4 × etiology (0: cholestatic or alcoholic, 1: otherwise).
Statistical analysis
Quantitative result was represented by mean ± standard deviation (SD) and analyzed using the paired Student's t test. Counting analysis has been represented by case number and percentage and statistical analysis was performed by means of χ 2 . The validity of the predictor model was measured by the concordance (c)-statistic. The difference of the MELD scores was analyzed by Kaplan-Meier survival curve. Cox proportional hazard analysis was used to select the risk factor. A P value<0.05 was considered statistically significant.
RESULTS
MELD scores
The patients were divided into three categories according to the MELD scores: MELD ≤30, 30<MELD<40 and MELD ≥40. those with 30<MELD <40 in 53% (32/60, 14 in MARS group and 18 in non-MARS group), those with MELD scores 40 or more in 30% (18/60, 10 in MARS group and 8 in non-MARS group).
Reliability of MELD score system
In MARS group, the 3-month mortality was 20% in subgroup MELD ≤ 30, 50% in subgroup 30<MELD<40 and 90% in subgroup MELD score≥ 40. Mortality increased as the MELD score increased, with significant difference among the three subgroups (P<0.05, Table) .
Curative effect of MARS treatments
A significant difference was found in mortality at 90 days from date of referral between MARS group and non-MARS group with MELD≤30 and 30<MELD<40 (P<0.05). No significant difference was found in mortality between MARS group and non-MARS group (P>0.05) with MELD≥40 (Table) .
Accuracy of the prediction ability of MELD score
The c-statistic for the MELD score's prediction of 3-month survival in non-MARS group was 0.86 [95% confidence interval (CI) 0.76-0.98, the best cutoff value was 25]. The mortality in subgroup MELD score≥25 was 82% (22/27), and the survival rate in subgroup MELD score<25 was 75% (3/4, sensitivity was 93% and specificity was 87%, P<0.05), the accuracy of prediction was 81% (25/31, Fig. 1 ). The c-statistic in MARS group was 0.78 (95% CI 0.66-0.89, the best cutoff value was 32). The mortality in subgroup MELD score≥32 was 60% (16/23) and in subgroup MELD score<32 was 83% (5/6, sensitivity was 80% and specificity was 50%, P<0.05), the accuracy of prediction was 72% (21/29, Fig. 2 ). There was significant difference between MARS group and non-MARS group in survival rate above and below the cutoffs (P<0.05).
The related variables analysis
Cox proportional hazard analysis was used to determine 
DISCUSSION
Mayo clinic group reported the MELD score system in 2000, which was originally developed to predict the outcomes of transjugular intrahepatic portosystemic shunts procedure in cirrhotic patients, 2 MELD was later used to evaluate the short-term survival prognosis of patients with different stages of liver cirrhosis. [3] [4] [5] Recently the model scoring system is used as the policy of determining priority in donor liver allocation for liver transplantation in America and predicting the mortality of patients before the transplant operation. 3 Said A et al 6 recently reported MELD score was able to predict short-and intermediate-term mortality across a broad spectrum of liver disease accurately.
Sixty chronic severe hepatitis patients were analyzed using MELD score in this study. The results show the 3-month mortality rises as the MELD score increases. We analyzed the curative effect of MARS treatment in chronic severe hepatitis patients using MELD score. MARS treatment is able to improve the short-term survival of some chronic severe hepatitis patients with MELD<40, and it should be carried out as early as possible in these patients when the curative effect of standard medical therapy is poor. MARS treatment can not improve the short-term survival of chronic severe hepatitis patients with MELD≥40. This provides us with reference criterion for choosing cases to undergo MARS and avoiding medical resources waste.
We use receiver operating characteristic (ROC) curve to analyze the prediction accuracy. The MELD score is able to predict the short-term prognosis of chronic severe hepatitis accurately. The relationship of the MELD scores in two weeks with the 3-month prognosis show the dynamic changes of the MELD scores reflect the degree of advanced stage and liver functional impairment exactly, and help identify the patients who are at higher risk of death.
In summary, MELD score is a useful index of degree of liver disease severity, the risk of death within 3 months increases with the rising MELD score. MELD score is able to accurately predict the short-term prognosis of the patients with chronic severe hepatitis. MARS artificial liver support treatment is safe and effective for the chronic severe hepatitis patients with an admission MELD score of 20-40. Whether or not chronic severe hepatitis patients receive MARS treatment and liver transplantation and the choice of the time of MARS treatment depend on the MELD score. In clinics, many of the MELD's characteristics, such as the use of easily available, objective parameters, as well as its advantage over the CTP scores (lack of ceiling or floor effect and stability of laboratory measures), make the wide application of the MELD scores in diverse clinical circumstances.
